ÜBERMAB Trademark

Trademark Overview

On Tuesday, February 17, 2009, a trademark application was filed for ÜBERMAB with the United States Patent and Trademark Office. The USPTO has given the ÜBERMAB trademark a serial number of 77672215. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 8, 2012. This trademark is owned by Synageva Biopharma Corp.. The ÜBERMAB trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for use in ex vivo and in vivo treatment of cancer, inflammation and infectious diseases
Übermab

General Information

Serial Number77672215
Word MarkÜBERMAB
Filing DateTuesday, February 17, 2009
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 8, 2012
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 16, 2009

Trademark Statements

Goods and Servicespharmaceutical preparations for use in ex vivo and in vivo treatment of cancer, inflammation and infectious diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, February 20, 2009
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSynageva Biopharma Corp.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressAthens, GA 30605
Party NameSynageva Biopharma Corp.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAthens, GA 30605

Trademark Events

Event DateEvent Description
Tuesday, October 9, 2012ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, October 8, 2012ABANDONMENT - NO USE STATEMENT FILED
Wednesday, May 23, 2012ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, May 23, 2012TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, February 22, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 21, 2012EXTENSION 5 GRANTED
Wednesday, February 15, 2012EXTENSION 5 FILED
Wednesday, February 15, 2012TEAS EXTENSION RECEIVED
Tuesday, August 16, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, August 13, 2011EXTENSION 4 GRANTED
Tuesday, August 2, 2011EXTENSION 4 FILED
Tuesday, August 2, 2011TEAS EXTENSION RECEIVED
Thursday, March 17, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 16, 2011EXTENSION 3 GRANTED
Tuesday, March 8, 2011EXTENSION 3 FILED
Tuesday, March 8, 2011TEAS EXTENSION RECEIVED
Thursday, September 16, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 15, 2010EXTENSION 2 GRANTED
Wednesday, August 18, 2010EXTENSION 2 FILED
Monday, September 13, 2010CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 18, 2010TEAS EXTENSION RECEIVED
Friday, October 2, 2009EXTENSION 1 GRANTED
Friday, October 2, 2009EXTENSION 1 FILED
Friday, October 2, 2009TEAS EXTENSION RECEIVED
Tuesday, September 8, 2009NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 16, 2009PUBLISHED FOR OPPOSITION
Wednesday, May 27, 2009NOTICE OF PUBLICATION
Tuesday, May 12, 2009LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, May 7, 2009APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, May 7, 2009ASSIGNED TO EXAMINER
Thursday, May 7, 2009PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Wednesday, May 6, 2009ASSIGNED TO LIE
Tuesday, May 5, 2009TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, February 20, 2009NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, February 20, 2009NEW APPLICATION ENTERED IN TRAM

Related Keywords

bermab vivo infectious diseases inflammation treatment preparations pharmaceutical cancer